AbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, expected to surpass $15 billion by 2027, with neuroscience and oncology portfolios also showing strong growth. AbbVie has delivered 11 consecutive years of dividend increases, with a 7.23% five-year CAGR and a current yield of 3.43%, rewarding shareholders consistently.
AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors. The company has successfully transitioned from Humira, with Rinvoq and Skyrizi driving impressive revenue growth and offsetting patent expirations. AbbVie's robust pipeline and strategic acquisitions position it for continued growth, supporting ongoing dividend increases and shareholder returns.
The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market.
![]() 4AB 8 months ago | Other | €1.55 Per Share |
![]() 4AB 11 months ago | Other | €1.55 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Jan 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Oct 2023 | Other | €1.48 Per Share |
23 Jul 2025 (38 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | 0.8 EPS |
25 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() 4AB 8 months ago | Other | €1.55 Per Share |
![]() 4AB 11 months ago | Other | €1.55 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Jan 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Oct 2023 | Other | €1.48 Per Share |
23 Jul 2025 (38 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | 0.8 EPS |
25 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | XETRA Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.